ArticleEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.

Allen B King et al.PubMed ↗Publisher ↗

No numbers read from the abstract.